Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Patrick Oellers; Aaron Savar; Felipe Samaniego; Barbara Pro; Bita Esmaeli

doi:10.1097/IOP.0b013e31824ab228

Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Patrick Oellers
, Aaron Savar
, Felipe Samaniego
, Barbara Pro
, Bita Esmaeli

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.

Original language	English (US)
Pages (from-to)	e145-e146
Journal	Ophthalmic plastic and reconstructive surgery
Volume	28
Issue number	6
DOIs	https://doi.org/10.1097/IOP.0b013e31824ab228
State	Published - Nov 2012

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.1097/IOP.0b013e31824ab228

Cite this

@article{b664923718c346a29fc20694a493c2ca,

title = "Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab",

abstract = "Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.",

author = "Patrick Oellers and Aaron Savar and Felipe Samaniego and Barbara Pro and Bita Esmaeli",

year = "2012",

month = nov,

doi = "10.1097/IOP.0b013e31824ab228",

language = "English (US)",

volume = "28",

pages = "e145--e146",

journal = "Ophthalmic plastic and reconstructive surgery",

issn = "0740-9303",

publisher = "Wolters Kluwer Health",

number = "6",

}

TY - JOUR

T1 - Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

AU - Oellers, Patrick

AU - Savar, Aaron

AU - Samaniego, Felipe

AU - Pro, Barbara

AU - Esmaeli, Bita

PY - 2012/11

Y1 - 2012/11

N2 - Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.

AB - Lymphoma of mucosa-associated lymphoid tissue (MALT) is the most common variety of lymphoma seen in the ocular adnexae. The authors present the case of a patient with MALT lymphoma refractory to treatment with rituximab. Subsequent treatment with 90Yttrium-Ibritumomab tiuxetan yielded a complete response.

UR - https://www.scopus.com/pages/publications/84870253474

UR - https://www.scopus.com/pages/publications/84870253474#tab=citedBy

U2 - 10.1097/IOP.0b013e31824ab228

DO - 10.1097/IOP.0b013e31824ab228

M3 - Article

C2 - 22820440

AN - SCOPUS:84870253474

SN - 0740-9303

VL - 28

SP - e145-e146

JO - Ophthalmic plastic and reconstructive surgery

JF - Ophthalmic plastic and reconstructive surgery

IS - 6

ER -

Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this